Keymed Biosciences Inc. (HKG:2162)
Hong Kong · Delayed Price · Currency is HKD 60.55
+2.90 (5.03%)
At close: Mar 27, 2026
Keymed Biosciences Revenue
In the year 2025, Keymed Biosciences had annual revenue of 716.31M CNY with 67.31% growth. Keymed Biosciences had revenue of 498.75M in the half year ending June 30, 2025, with 52.47% growth.
Revenue
716.31M CNY
Revenue Growth
+67.31%
P/S Ratio
22.38
Revenue / Employee
487.62K CNY
Employees
1,469
Market Cap
17.84B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 716.31M | 288.19M | 67.31% |
| Dec 31, 2024 | 428.12M | 74.03M | 20.91% |
| Dec 31, 2023 | 354.10M | 254.03M | 253.87% |
| Dec 31, 2022 | 100.06M | -10.21M | -9.26% |
| Dec 31, 2021 | 110.27M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Genscript Biotech | 7.47B |
| Zai Lab | 3.58B |
| InnoCare Pharma | 2.64B |
| Duality Biotherapeutics | 2.06B |
| Everest Medicines | 1.90B |
| Ascentage Pharma Group International | 638.89M |
| CStone Pharmaceuticals | 299.99M |
| Ascletis Pharma | 2.59M |